February 24, 2026- Cardinal Health released its 2026 Biosimilars Report: Driving access and patient outcomes in physician practices, which highlights the substantial savings biosimilars have delivered to the U.S. healthcare system and the strong confidence providers have in these treatments.
The report draws from insights gathered from 101 physician practices nationwide. Nearly 99% of providers surveyed said they feel comfortable explaining biosimilars to patients, underscoring the strong clinical confidence supporting these therapies. Predictable reimbursement remains essential for sustained adoption: 68% of practices rated consistent reimbursement as “very important,” while 59% favored set discount models over incremental price reductions that can disrupt reimbursement stability.
The report also explores a major advancement in biosimilar’s trajectory: the acceleration of oncology biosimilars, which now reach an average 81% market share within five years of launch. Over the next two years, we expect FDA approval of nearly 25 new biosimilars in therapeutic areas including immunology, oncology and retina.
Read the full 2026 Biosimilars Report.